Review Article
A Brief Review of Analytical Methods for the Estimation of Allopurinol in Pharmaceutical Formulation and Biological Matrices
Table 1
UV-visible and spectrofluorimetric methods for the determination of allopurinol.
| S. no. | Drugs | Pharmaceutical matrix | Wavelength (nm) | Linearity (μg·mL−1) | Assay (%) | Accuracy of the study (%) | Ref. |
| UV-visible spectrophotometric methods | 1. | ALLP | Tablet | 580 | 2–10 | 98.2–102.5 | 100 | [16] | 2. | ALLP and LA | Tablet | 250 and 310–390 | 10–50 | 101.2 and 100.69 | 101.18–101.61 and 100.81–101.84 | [17] | 3. | ALLP | Tablet | 450 and 515 | 10–70 | 101.1 and 101.4 | 98.40–100.7 and 98.20–100.4 | [18] | 4. | ALLP and UA | Urine | 284 and 293 | 0.2–1.2 mg/100 ml | 99.25 and 98,97 | 100.14 and 100.23 | [19] | 5. | ALLP and FC | Tablet | 281 and 275 | 0.25–3.5 | 99.01–102.24 and 99.88–101.89 | 99.75 and 99.84 | [20] | 6. | ALLP and LSD | Tablet | 252–228, 240, and 290 | 1–16 μg mL–1 and 3–45 μg mL–1 | 99.98–100.23 and 100.05 | 99.77–100.22 and 100.26 | [21] |
| Spectrofluorimetry | 7. | CM, TB, CB, and ALLP | Tablet | 535/365 | 1–6 for CM and CB, 0.75–6 for TB, and 4–16 for ALLP | — | 99.75–101.04 | [23] | 8. | LSD and ALLP | Tablet and human plasma | 288/343 465/535 | 0.25–4.0 μg mL–1 for LSD and 0.2–20 μg mL–1 for ALLP | 100.41 and 99.28 | 99.55 and 100.18 | [24] |
|
|